AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01282970
Drug: BI 135585
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
Trial: NCT00639743
Drug: tenecteplase (group A)
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tenecteplase (group A)
Trial: NCT02506985
Drug: rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immediately following completion of alteplase infusion, patients will receive rivaroxaban 15 mg oral bid for 21 days followed by 20 mg oral daily.
Trial: NCT02506985
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediately following completion of alteplase infusion, patients will continue on unfractionated heparin or low-molecular weight heparin with initiation of warfarin adjusted to INR of 2-3.
Trial: NCT03712423
Drug: Cripec Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 89 Zirconium Cripec Docetaxel PET
Trial: NCT00281658
Drug: Lapatinib (GW572016) oral tablets
RxNorm normalized name: lapatinib Oral Tablet
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1500 mg oral daily continuously
Trial: NCT00281658
Drug: Paclitaxel infusion
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months
Trial: NCT02012296
Drug: enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02012296
Drug: mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01916863
Drug: canagliflozin 300 mg
RxNorm normalized name: canagliflozin 300 MG
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02151773
Drug: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
RxNorm normalized name: Measles virus vaccine live attenuated
DrugBank: Measles virus vaccine live attenuated (DB10315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
Trial: NCT02551991
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03576794
Drug: Leflunomide 20 mg
RxNorm normalized name: leflunomide 20 MG
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
Trial: NCT00390091
Drug: abetimus sodium (LJP 394)
RxNorm normalized name: abetimus
DrugBank: Abetimus (DB06662)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00551928
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High dose Melphalan 200mg/sm with autologous stem cell support
Trial: NCT00551928
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Six months of oral therapy with Lenalidomide 10mg/day given 21 days in every 28 days cycle with the combination ofMelphalan and steroids (day 22 to 28), for 6 cycles every 28 days.
Trial: NCT00551928
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally at the dose of 2 mg/Kg for 4 days followed by a 24 day rest period (days 5 to 28), for 6 cycles every 28 days
Trial: NCT00551928
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan will be given orally at the dose of 0.18 mg/Kg for 4 days, followed by a 24 days rest period (day 5 to 28)for 6 cycles every 28 days
Trial: NCT01884909
Drug: Metoprolol Succinate ER Tablet 200 mg
RxNorm normalized name: metoprolol succinate Extended Release Oral Tablet
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 \* 200 mg tablet per day
Trial: NCT03906565
Drug: utidelone injection
RxNorm normalized name: Utidelone
DrugBank: Utidelone (DB17575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: utidelone monotherapy in patients with advanced or metastatic CRC by iv transfusing utidelone injection
Trial: NCT00120380
Drug: Aerosolized iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03311386
Drug: Actilyse
RxNorm normalized name: Actidose
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thrombolytic therapy
Trial: NCT01199367
Drug: KW-2450 in combination with lapatinib and letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three subjects will be assigned to each of 4 sequential cohorts. Dose escalation may proceed once at least 3 subjects have completed 30 days of study treatment. Subjects who withdraw prior to completing Day 30 for reasons other than DLT will be replaced. If a DLT is observed, additional subjects may be enrolled so that up to 6 subjects are enrolled at that dose level.
Trial: NCT00450008
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fixed dose of 250 mcg/m2, 3 days per week by subcutaneous injection
Trial: NCT00450008
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide by oral administration at a fixed dose of 200 mg. Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration. Thalidomide and Coumadin will be given daily at bedtime without interruption.
Trial: NCT00450008
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administered by intravenous piggyback over 1 hour at 75mg/m² every 3 weeks. Pre-medication for the docetaxel infusion will consist of dexamethasone 8 mg administered orally 12 hours, 3 hours and 1 hour before docetaxel.
Trial: NCT01004198
Drug: MP4OX
RxNorm normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4.3 g/dL PEG-Hb solution in lactated electrolyte solution
Trial: NCT01004198
Drug: Ringers Lactate solution
RxNorm normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringers Lactate solution for Injection
Trial: NCT02236182
Drug: Ipratropium Bromide low dose
RxNorm normalized name: ipratropium bromide Metered Dose Inhaler
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02236182
Drug: Ipratropium Bromide high dose
RxNorm normalized name: ipratropium bromide Metered Dose Inhaler
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01448213
Drug: Fluorometholone
RxNorm normalized name: Fluorometholone
DrugBank: Fluorometholone (DB00324)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
Trial: NCT02530801
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
Trial: NCT03830723
Drug: Follitropin delta
RxNorm normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Study medication doses during all 3 insemination will be personalized using a suggested algorithm
Trial: NCT01898624
Drug: mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01711034
Drug: OPB-111077
RxNorm normalized name: OPB-111077
DrugBank: OPB-111077 (DB16630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation phase starting with dose of 100mg tablets on Day 1 and 4, and all remaining days of each 28 day cycle until disease progression or toxicity develops.~Dose expansion phase starting with daily dosing of 250mg for 28 day consecutive day cycles.
Trial: NCT00755209
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading 1 gram (\~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (\~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours
Trial: NCT02558829
Drug: Macimorelin
RxNorm normalized name: Macimorelin
DrugBank: Macimorelin (DB13074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose
Trial: NCT02558829
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin, 0.10 U/kg (0.15 U/kg if BMI \> 30 kg/m2), intravenous injection, single dose
Trial: NCT00791973
Drug: fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 puffs in each nostril once daily for 1 week
Trial: NCT01408836
Drug: Methyl prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methyl prednisolone
Trial: NCT01275170
Drug: Imipenem + Cilastatin
RxNorm normalized name: cilastatin / imipenem
DrugBank: Cilastatin (DB01597)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg IV over 30 minutes as a single dose
Trial: NCT01275170
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam hcl syrup single 2.0 mg dose by mouth.
Trial: NCT01275170
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally
Trial: NCT00003892
Drug: ISIS 5132
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mg/kg/day IV for 21 days every 4 weeks.
Trial: NCT01104376
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily.
Trial: NCT01104376
Drug: voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily.
Trial: NCT00797966
Drug: OPC-34712
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks
Trial: NCT00740948
Drug: Rituximab (mabthera) Injection
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 \* 1g of Rituximab at the 1st day and at the 14th day.
Trial: NCT00301925
Drug: epirubicin hydrochloride
RxNorm normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01711814
Drug: peficitinib
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT01101269
Drug: Lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then take Lisinopril 10 mg every day for 7 days, after which they will undergo another CEU using Definity as the contrast agent.
Trial: NCT01852669
Drug: Hydration
RxNorm normalized name: Eucerin Daily Hydration
DrugBank: Avobenzone (DB09495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydration of patient with 0.5L NaCl and 20mg frusemide IV
Trial: NCT01121224
Drug: Blinded clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For non-ACS patients with no other clinical indication for open-label thienopyridine who receive one or more DES in the target lesion.
Trial: NCT01121224
Drug: Thienopyridine (open-label)
RxNorm normalized name: Phenopyridine
DrugBank: Oxyquinoline (DB11145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.
Trial: NCT04035005
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg infusion every 24 weeks. A minimum interval of 20 or 22 weeks, depending if the previous dose was administered in one or two infusion, should be maintained between each infusion.
Trial: NCT03574818
Drug: Necitumumab-Gemcitabine-Cisplatin
RxNorm normalized name: Necitumumab
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Gemcitabine 1250mg/m2 IV on D1, D8~* Cisplatin 75mg / m2 IV on D1~* Necitumumab 800mg IV on D1, D8 (peripheral blood for effector cells and cytokine measurements prior to each cycle) Repeat cycle every 21 days up to 3 cycles.
Trial: NCT03162120
Drug: Ranolazine plus Metoprolol Combination
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
Trial: NCT03162120
Drug: FlecainidE pluS Metoprolol Combination
RxNorm normalized name: metoprolol and thiazides, combinations
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
Trial: NCT03153319
Drug: Adalimumab Injection [Humira]
RxNorm normalized name: adalimumab Injection [Humira]
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Investigational Drug
Trial: NCT00104598
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01018784
Drug: MORAb-009
RxNorm normalized name: Immunoglobulin G1, anti-(mesothelin) (human-mouse monoclonal MORAb-009 heavy chain), disulfide with human-mouse monoclonal MORAb-009 .Kappa.-chain, dimer
DrugBank: Amatuximab (DB12845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle.
Trial: NCT02350764
Drug: nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02350764
Drug: pilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00485797
Drug: Ritalin
RxNorm normalized name: Ritalin
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The effect of ritalin on postural stability of ADHD childrens will be measured using RCT study design
Trial: NCT00103350
Drug: TG100-115
RxNorm normalized name: TG100-115
DrugBank: TG100-115 (DB05552)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01929941
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency
Trial: NCT01929941
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency
Trial: NCT01502800
Drug: ARQ 761
RxNorm normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ 761 will be administered intravenously at a starting dose of 195 mg/m2 IV once weekly. Depending on toxicities observed, up to seven treatment cohorts will be enrolled with dose escalation occurring by doubling (first escalation) and 40% increments thereafter. If dosing is tolerated at all levels and pharmacokinetic data suggest continued escalation is warranted, additional dose levels will
Trial: NCT02128685
Drug: Dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01502800
Drug: ARQ 761 Weekly Administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 each week for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2.
Trial: NCT01502800
Drug: Bi-Weekly Administration of ARQ 761
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein bi-weekly via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 bi-weekly for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2.
Trial: NCT01502800
Drug: Two Consecutive Weeks Administration of ARQ 761 with one week of rest
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 for 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2.
Trial: NCT00171080
Drug: valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00171080
Drug: irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00359073
Drug: montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg everyday
Trial: NCT00213993
Drug: antiperspirant
RxNorm normalized name: AXE Antiperspirant, Essence
DrugBank: Aluminum chlorohydrate (DB11573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiperspirant topically once daily to one foot
Trial: NCT02743611
Drug: Rimiducid
RxNorm normalized name: Rimiducid
DrugBank: Rimiducid (DB04974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity
Trial: NCT01317108
Drug: CMF Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04444856
Drug: Eptacog alfa (activated)
RxNorm normalized name: Eptacog alfa (activated)
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: The women included in the study population have been treated with NovoSeven® (eptacog alfa (activated)) according to local routine clinical practice at the discretion of the treating physician.
Trial: NCT00317031
Drug: Acamprosate or Naltrexone
DrugBank: Acamprosate (DB00659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mg\&d 90 days
Trial: NCT03390010
Drug: Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergine
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
Trial: NCT03390010
Drug: Syntocinon and using extra uterotonic drugs when needed ; methergine carboprost
DrugBank: Carboprost (DB19356)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost